PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy by Frère, Antoine et al.
 
 
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for 
all UGent research publications. Ghent University has implemented a mandate stipulating 
that all academic publications of UGent researchers should be deposited and archived in this 
repository. Except for items where current copyright restrictions apply, these papers are 
available in Open Access. 
 
This item is the archived peer‐reviewed author‐version of: PEGylated and Functionalized 
Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 
siRNA in Cancer Therapy      
Authors: Frere A., Baroni A., Hendrick E., Delvigne A.S., Orange F., Peulen O., Dakwar G.R., 
Diricq J., Dubois P., Evrard B., Remaut K., Braeckmans K., De Smedt S.C., Laloy J., Dogne J.M., 
Feller G., Mespouille L., Mottet D., Piel G.         
In: ACS Applied Materials & Interfaces 2017, 9(3): 2181‐2195 
 
To refer to or to cite this work, please use the citation to the published version: 
Frere A., Baroni A., Hendrick E., Delvigne A.S., Orange F., Peulen O., Dakwar G.R., Diricq J., 
Dubois P., Evrard B., Remaut K., Braeckmans K., De Smedt S.C., Laloy J., Dogne J.M., Feller G., 
Mespouille L., Mottet D., Piel G. (2017) 
PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for 
Intravenous Administration of HDAC5 siRNA in Cancer Therapy      
ACS Applied Materials & Interfaces 9(3): 2181‐2195 
DOI: 10.1021/acsami.6b15064  
 
          
 
 
 
 
 
 
 
 
 
  
 
1 
 
PEGylated and functionalized aliphatic polycarbonate polyplex 
nanoparticles for intravenous administration of HDAC5 siRNA in cancer 
therapy 
Antoine Frèrea,c, Alexandra Baronib, Elodie Hendrickc, Anne-Sophie Delvigned, François Orangee, 
Olivier Peulenf, George R. Dakwarg, Jérôme Diricqb, Philippe Duboisb, Brigitte Evrarda, Katrien 
Remautg, Kevin Braeckmansg, Stefaan C. De Smedtg, Julie Laloyd, Jean-Michel Dognéd, Georges 
Fellerh, Laetitia Mespouilleb, Denis Mottetc†, Géraldine Piela*† 
 
aLaboratory of Pharmaceutical Technology and Biopharmacy (LTPB) – Center for Interdisciplinary 
Research on Medicines (CIRM), University of Liege, Avenue Hippocrate 15 - 4000 Liege, Belgium 
bLaboratory of Polymeric and Composite Materials, Center of Innovation and Research in Materials 
and Polymers (CIRMAP), Research Institute for Health Sciences and Technology, University of Mons, 
Place du Parc 20 - 7000 Mons, Belgium 
cProtein Signalisation and Interaction (PSI) – GIGA, University of Liege, Avenue de l’Hopital 11 - 4000 
Liege, Belgium 
dNamur Nanosafety Center (NNC), NAmur Research Institute for LIfe Sciences (NARILIS), Department 
of Pharmacy, University of Namur, Rue de Bruxelles 61 - 5000 Namur, Belgium 
eCentre Commun de Microscopie Appliquée, University of Nice – Sophia Antipolis, Parc Valrose – 
06108 Nice, France 
fMetastasis Research Laboratory (MRL) – GIGA, University of Liege, Avenue Hippocrate 15 - 4000 
Liege, Belgium 
gLaboratory for General Biochemistry and Physical Pharmacy, Ghent Research Group on 
Nanomedicines, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460 - 9000 Ghent, 
Belgium. 
hLaboratory of Biochemistry, Centre for Protein Engineering (CIP), University of Liège, Allée du 6 Août 
13 - 4000 Liège, Belgium. 
*Corresponding Author: 
E-mail: geraldine.piel@ulg.ac.be, Phone: +3243664308, Fax: +3243664302. 
†G. Piel and D. Mottet contributed equally to this work.  
2 
 
Abstract 
Guanidine and morpholine functionalized aliphatic polycarbonate polymers able to efficiently deliver 
histone deacetylase 5 (HDAC5) siRNA into the cytoplasm of cancer cells in vitro leading to a decrease 
of cell proliferation were previously developed. To allow these biodegradable and biocompatible 
polyplex nanoparticles to overcome the extracellular barriers and be effective in vivo after an 
intravenous injection, polyethylene glycol chains (PEG750 or PEG2000) were grafted on the polymer 
structure. These nanoparticles, showed an average size of about 150 nm and a slightly positive zeta 
potential with complete siRNA complexation. Behavior of PEGylated and non-PEGylated polyplexes 
were investigated in the presence of serum, in terms of siRNA complexation (Fluorescence Correlation 
Spectroscopy), size (Dynamic Light Scattering and Single-Particle Tracking), interaction with proteins 
(Isothermal Titration Calorimetry) and cellular uptake. Surprisingly, both PEGylated and non-
PEGylated formulations presented relatively good behavior in the presence of fetal bovine serum (FBS). 
Hemocompatibility tests showed no effect of these polyplexes on hemolysis and coagulation. In vivo 
biodistribution in mice was performed and showed a better siRNA accumulation at the tumor site for 
PEGylated polyplexes. However, cellular uptake in protein-rich conditions showed that PEGylated 
polyplex lost their ability to interact with biological membranes and enter into cells, showing the 
importance to perform in vitro investigations in physiological conditions closed to in vivo situation. In 
vitro, the efficiency of PEGylated nanoparticles decreases compared to non-PEGylated particles, 
leading to the loss of the antiproliferative effect on cancer cells. 
Keywords: siRNA; polyplex nanoparticles; intravenous administration; aliphatic polycarbonate; 
polyethylene glycol; protein corona.  
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1. Introduction 
In oncology, histone deacetylases (HDAC) family members are considered as a promising novel class 
of anti-cancer targets.1 These HDAC are actually targeted by broad-spectrum pharmacological HDAC 
inhibitors (HDACi).1 These unselective HDACi show promising anti-tumoral activity both in vitro and 
in vivo. Based on their potent anti-cancer effects, they are currently being tested in various human 
clinical trials and some of them like Suberoylanilide hydroxamic acid (SAHA, Vorinostat®), 
Romidepsin (Depsipeptide, FK228, Istodax®), Belinostat (PXD101, Beleodaq®), and Panobinostat 
(LBH589, Farydak®) were US FDA and/or EMA approved for the treatment of refractory or relapsed 
cutaneous T-cell lymphomas, validating the concept of HDAC inhibition to treat cancer patients.2-4 
Despite promising results in the treatment of hematological disorders, there is a need to improve the 
efficacy of these drugs in the clinic.5 One way for such improvement is the development of more specific 
inhibitor directed against individual HDAC. By targeting one of the most relevant HDAC members 
critically involved in tumor progression, it may be possible to greatly improve the efficacy with the 
additional advantage of removing certain toxicities that may be associated with the inhibition of multiple 
HDAC.5 The development of selective pharmacological HDAC inhibitors specifically targeting one 
HDAC member might be a difficult task, at least because these enzymes share a highly conserved 
catalytic domain.6 A siRNA–based strategy might be therefore a better approach to selectively target 
relevant HDAC for cancer therapy. Preclinical investigations by targeted knockdown of HDAC 
demonstrated that HDAC5 silencing blocked cell proliferation, cell survival and reduced tumor growth 
in vivo suggesting that selective inhibition of HDAC5 using siRNA could yield clinical benefit for 
cancer treatment.7-9  
Since the discovery of RNA interference mechanism (RNAi) at the end of the last century,10 many 
researchers have tried to exploit its potential in the treatment of various human diseases, such as 
cancer.11-12 The administration of specific small interfering RNA (siRNA) to the cytoplasm leads to the 
degradation of complementary messenger RNA (mRNA), and therefore the shutdown of the target 
protein.13-14 However, the way into the cytoplasm is paved with extracellular and intracellular barriers. 
Naked siRNA exhibits a short half-life in the bloodstream due to rapid degradation by serum nucleases.15 
4 
 
In addition, the high molecular weight and the negative charge also prevent the passage of siRNA 
through cell membranes. Vectors are thus required to transport and deliver siRNA into the cells. To 
obtain a therapeutic efficiency, these have to overcome numerous extracellular (nuclease degradation, 
plasma protein aggregation, recognition by the immune system, tumor accumulation, etc.) as well as 
intracellular barriers (endocytosis, endosomal escape, and siRNA release into the cytoplasm).16-20 
To deliver siRNA directed against HDAC5 mRNA, we have previously developed original aliphatic 
polycarbonate polymers,21-25 grafted with guanidine and morpholine functional groups. The guanidine 
function, cationic at neutral pH, is necessary for both siRNA binding and interactions with the negatively 
charged plasma membranes.26-27 The morpholine function, weak base and ionizable in acidic pH, confers 
buffer capacity to the polymer and helps to escape from the endosome using the “proton sponge” effect.28 
In addition to these functionalized blocks, the polymer contains a hydrophobic chain of 
poly(trimethylene) carbonate (PTMC), bringing an amphiphilic character to the polymer, and thus 
allowing it to form nanoparticles in aqueous solution.29-31 As shown in our previous study,25 the 
combination of both morpholine and guanidine functionalities at a ratio above 1 with the presence of a 
hydrophobic group on the copolymer structure seems to be crucial to overcome intracellular barriers, 
ultimately leading to protein downregulation activity of siRNA polyplex nanoparticles. This new 
polycarbonate polymer is called P-G-M for Polycarbonate-Guanidine-Morpholine polymer. Beyond the 
requested functions to achieve polyplex formation and transport, the aliphatic polycarbonate backbone 
is fully biocompatible and bioresorbable32, making this family of polymer very promising for gene 
therapy as the vector is degraded after its task is achieved. Such fine-tuned synthetic polymer vector can 
be produced through a metal-free polymerization process involving nontoxic catalysts in mild conditions 
and giving access to any kind of functional polymers and topologies.33-35 
The objective of the present work is to further modify these polymers to enable them to overcome the 
extracellular barriers and induce biological activity in vivo following intravenous injection. Once 
intravenously injected, polyplexes may interact with different components of the bloodstream. 
Understanding the influence of the presence of serum on the stability of nanoparticles is crucial to reach 
a therapeutic efficiency. Indeed, the high amount of anionic serum proteins can interact and cover the 
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surface of cationic nanovectors, forming a “protein corona” around the particle.36 The formation of this 
corona changes the identity of the nanovectors. First, the negatively charged proteins can compete with 
the siRNA on the binding to the nanovectors, resulting in a premature release of the siRNA in the 
bloodstream.37 Secondly, the protein corona can modify the size and the aggregation state, resulting in 
too large particles for an optimal accumulation at the tumor site through the Enhanced Permeability and 
Retention (EPR) effect.38-39 Moreover, aggregation modifies pharmacokinetics which in turn might affect 
the tissue distribution and penetration.40 The corona can also change the surface properties of the 
nanoparticles, lowering the interaction with plasma membranes and thus interfering with cellular uptake 
and endosomal escape, crucial steps for the polyplex efficiency. In addition, hemocompatibility is a 
major concern, to safe translation into the clinic, the injection of polyplexes should not cause hemolysis 
and should not disturb the normal functions of the blood system, like platelet activation and 
coagulation.41 
Even if this strategy is sometimes controversial42, the most common method to overcome interaction 
with blood constituents is PEGylation of nanoparticles. The polyethylene glycol (PEG) shielding around 
the particle is supposed to reduce the interaction with plasma proteins; depending on the coverage 
density, the conformation and the molecular weight of PEG chains.43-45 Two types of PEG were grafted 
on the previously described polymer: PEG750 and PEG2000. These two polymers were compared to the 
non-PEGylated amphipathic polycarbonate polymer used in our previous work. The suitability of these 
nanoparticles for IV injection was evaluated studying siRNA protection against nucleases, behavior in 
the presence of serum (understanding of nanoparticle-protein interaction, release of siRNA, size 
stability, and cellular uptake), cytotoxicity and hemocompatibility testing, and in vivo tumor 
accumulation in mouse model. Finally, the biological efficiency of these nanovectors was determined, 
in order to highlight a decrease of proliferation of cancer cells.   
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2. Materials and Methods 
2.1. Materials 
HDAC5 siRNA (sense strand: 5’-CAG-CAU-GAC-CAC-CUG-ACA-ATT-3’; antisense strand: 5’-
UUG-UCA-GGU-GGU-CAU-GCU-GTT-3’), GL3 siRNA (sense strand: 5’-CUU-ACG-CUG-AGU-
ACU-UCG-ATT-3’; antisense strand: 5’-UCG-AAG-UAC-UCA-GCG-UAA-GTT-3’) and Alexa 
Fluor® 546, 647 and 660 labeled siRNAs were provided by Eurogentec (Seraing, Belgium). Nuclease-
Free Water was purchased from Ambion (Life Technologies, Gent, Belgium). 20X TE (Tris-EDTA, pH 
7.5) buffer was obtained from Invitrogen (Life Technologies, Gent, Belgium). Mannitol was purchased 
from Certa (Braine-l’Alleud, Belgium). Heparin sodium salt from porcine intestinal mucosa (200 USP 
units/mg), and ethidium bromide solution (BET) were provided by Sigma-Aldrich (Diegem, Belgium). 
Fetal bovine serum (FBS) was obtained from Gibco (Life Technologies, Gent, Belgium). 
2.2. Typical procedure for the organocatalytic ROP of cyclic carbonates in the synthesis of 
aliphatic polycarbonate copolymers 
In a glovebox, a glass vial was charged with the (macro)initiator (BzOH for P-G-M, PEO750 and PEO2000 
for P-G-M-PEG750 and P-G-M-PEG2000, respectively), the catalyst (DBU) and methylene chloride. The 
solution was maintained under magnetic stirring until homogeneity was reached. Then, the first 
monomer (TMC for P-G-M, CM for P-G-M-PEG750 and P-G-M-PEG2000) dissolved in methylene 
chloride was one-shot added to give a final monomer concentration of 1 M. The initial molar ratio of 
initiator to catalyst used for each synthesis was 1:5 (ROH:DBU). The vial was sealed and maintained 
under vigorous stirring until a monomer conversion higher than 90 % was reached (as observed by SEC). 
Polymer chains were directly extended by subsequent addition of the second (Boc-CG) and the third 
(CM for P-G-M, TMC for P-G-M-PEG750 and P-G-M-PEG2000) monomers, dissolved in a minimum of 
DCM, a soon as the previous monomer conversion has reached 90 % (as observed by SEC). 
Polymerizations were quenched with a dash of Amberlyst® 15-H and the polymers were recovered after 
dropwise precipitation in cold n-heptane under vigorous stirring. The resulting copolymers were dried 
overnight under reduced pressure at room temperature. The polymer samples were characterized by SEC 
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in THF + 2 wt % NEt3 and 1H-NMR in CDCl3 to determine the macromolecular parameters, as 
previously described 25. The Boc protecting groups of the guanidinium moieties were eliminated using 
TFA in a 5 mL stirred solution of DCM/TFA 4/1 v/v for 18 hours at room temperature. Volatiles were 
removed in vacuo and the polymers were dried overnight under reduced pressure at room temperature. 
Samples were stored into a desiccator maintained under vacuum to avoid moisture entrapment and 
potential hydrolysis. 
Table 1. Characterization of guanidine and morpholine based aliphatic polycarbonates obtained by 
organocatalytic ROP of functional cyclic carbonates (DCM, r.t., [M]0 = 1M).  
Abbreviation Sample DP(a) Mn(b) Ð(c) Ng(d) Nm(d) 
Nm/
Ng 
  CG CM (g.mol-1)  (nmol.µg-1)  
P-G-M Bz-PTMC37-b-PCG8-b-PCM8.5 
8 8.5 10100 1.4 0.79 0.84 1.1 
P-G-M-PEG750 
PEO750-PCM9.5-b-PCG8-
b-PTMC51 
8 9.5 12300 2.2 0.65 0.78 1.2 
P-G-M-PEG2000 
PEO2000-PCM16-b-
PCG10.5-b-PTMC63 
10.5 16 17700 2.2 0.60 0.90 1.5 
(a) As obtained by 1H NMR spectroscopy (500 MHz) in CDCl3 at r.t. 
(b) As calculated by 1H NMR spectroscopy (500 MHz) after BOC deprotection. 
(c) As obtained by SEC in THF + NEt3 (2 w%) at 35 °C before BOC deprotection. 
(d) Concentration of ionizable nitrogen atoms present in the polymer structure (N value), given by guanidinium functions (Ng) or morpholine 
functions (Nm) (nmol.µg-1). 
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Fig. 1. Chemical structures of P-G-M, P-G-M-PEG750 and P-G-M-PEG2000 polycarbonate polymers. 
2.3. Polyplexes formation 
Polyplexes were prepared by electrostatic interaction of the cationic copolymers with the negatively 
charged siRNA according to the N/P ratio. N/P corresponds to the ratio of the moles of the protonable 
amino groups (N) on the polymer to the moles of the phosphate groups (P) on siRNA. In practice, the 
N value corresponds to the concentration of guanidinium + morpholino functionalities (in nmol) per μg 
of polymer. Polymers were dissolved in TE buffer (pH 7.4, isotonized by mannitol) at a concentration 
of 1mg.mL−1. siRNA was dissolved in the same buffer at a concentration of 1μM. Complexes were 
obtained by addition of the siRNA solution to the cationic polymer solution, followed by the dilution to 
the desired concentration of siRNA. The mixture was immediately vortexed for 10 s and left for 30 min 
at room temperature for polyplexes formation.  
2.4. Size, zeta potential and siRNA complexation  
Size and surface charge (zeta potential) of polyplexes were determined at 100 nM of siRNA (N/P 40) 
using the Zetasizer Nano ZS® (Malvern Instruments, UK). The complexation rate of siRNA was 
determined by the Quant-iT™ RiboGreen® RNA reagent according to the manufacturer’s instructions 
(Invitrogen, Life Technologies, Gent, Belgium) 25. 
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2.5. Transmission Electron Microscopy (TEM) 
For TEM characterization, nanoparticles were negatively stained using the following procedure: a drop 
of polyplexes dispersion (5 µL, 300 nM siRNA final concentration, N/P 40) was placed on a glow 
discharged 300 mesh copper grid with a carbon support film for 3 minutes, and the excess solution was 
then removed with a filter paper. Staining was performed by adding a drop of 1 % uranyl acetate aqueous 
solution (w/v) on the grid for 2 minutes and then removing the excess solution. TEM observations were 
performed with a JEOL JEM-1400 transmission electron microscope, equipped with a Morada camera, 
at a 100 kV acceleration voltage. 
2.6. Nuclease resistance 
The protection of siRNA against nucleases when inside polyplexes was evaluated by gel retardation 
assay. 30 µL of polyplexes dispersion (500 nM siRNA, N/P 40) were incubated with or without 1 µL of 
RNAse A (50 µg/mL, Roche, Basel, Switzerland) for 1 hour. Then, 0.5 µL of RNAseOUT (Invitrogen, 
Life Technologies, Gent, Belgium) for RNAse A inactivation and 18.5 µL of heparin (2 mg/mL, Sigma-
Aldrich, Diegem, Belgium) for siRNA release were added. 40 µL of these samples mixed with 2 µL of 
glycerol and 2 µL of gel blue loading were loaded onto a 4 % agarose gel in TAE buffer containing 
0.01 % ethidium bromide. Electrophoresis was performed at 100 V for 1 hour in a Horizon 11.14 
horizontal gel electrophoresis apparatus (Biometra, Goettingen, Germany). The gel was visualized by 
exposure to UV-illumination by a Molecular Imager Gel Doc XR System (Bio-Rad, Hercules, USA). 
Controls are 300 nM siRNA, 300 nM siRNA + 1 µL of RNAse A, and 300 nM siRNA + 0.5 µL of 
RNAseOUT + 1 µL of RNAse A. 
2.7. Isothermal Titration Calorimetry (ITC) 
Interaction of polyplexes with Bovine Serum Albumin (BSA) was evaluated using ITC.46 ITC titrations 
were performed on a MicroCal ITC200 (GE-Malvern Instruments, UK) equipped with a 200 µL 
Hastelloy sample cell and an automated 40 µL glass syringe rotating at 1000 rpm. In order to avoid 
buffer mismatch and the generation of dilution heats, 5 mM BSA (332 mg/ml) (Sigma A7030, fatty 
acid-, protease- and globulin-free) were first dialyzed overnight at 4 °C against 200 mM Tris-HCl, 20 
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mM EDTA, pH 7.5 in RNase free water. Then, the dialysis buffer was used to prepare the nanoparticles. 
Control experiments indicated negligible heat signals for buffer injections into nanoparticles and 
dilution heats of BSA injections into buffer were subtracted from experimental data. In a standard 
experiment, nanoparticles formed by 11.12 µM polymer were titrated by 9 injections (4 µl) of 5 mM 
BSA at an interval of 150 s.  
The obtained data were fitted via nonlinear least squares minimization method to determine binding 
stoichiometry (n), association constant (Ka), and change in enthalpy of binding (ΔH°b) using ORIGIN 7 
software v.7 (OriginLab). The Gibbs free energy of binging, ΔG°b, was calculated from Ka and the 
entropic term, TΔS°b, was derived from the Gibbs-Helmholtz equation using a fixed ΔH°b value.  
2.8. Fluorescence Correlation Spectroscopy (FCS) 
Fluorescence Correlation Spectroscopy (FCS) was employed to determine the siRNA complexation 
stability in the presence of fetal bovine serum (FBS). FCS is a microscopy-based technique able to 
monitor the fluorescence intensity fluctuations of fluorescent siRNA diffusing in and out of the focal 
volume of a confocal microscope, enabling the determination of the percentage of complexed siRNA.47 
FCS measurements were performed on polyplex nanoparticles containing Alexa Fluor® 647 labeled 
siRNA. 5 µL of polyplexes dispersion (300 nM siRNA, N/P 40) were supplemented with TE buffer and 
FBS to reach a final volume of 50 µL, containing 10 or 50 % FBS (v/v). Samples were analyzed before 
FBS addition and after 1, 2, and 3 hours incubation at 37 °C following the experimental setup described 
previously.37 
2.9. Fluorescence Single-Particle Tracking (fSPT)  
Size stability of polyplexes in the presence of FBS was observed by Fluorescence Single-Particle 
Tracking (fSPT), a microscopy-based technique designed to observe the motion of individual 
fluorescent nanoparticles in solution. The fluorescent nature of siRNA in polyplex nanoparticles makes 
them visible in complex media, like FBS. According to the Brownian motion, size distribution can be 
deduced from the mobility of the sample.48 fSPT measurements were performed on the same samples 
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used in FCS, after 1 and 3 hours incubation at 37 °C following the experimental setup described 
previously.37 
2.10. Cell culture (HUVEC, HeLa and HCT116) 
HUVEC primary cells (human umbilical vein endothelial cells) were provided by Lonza (CC-2519, 
Verviers, Belgium) and cultured in EGM basal medium (Lonza). HeLa cancer cells (human cervical 
carcinoma cell line) were obtained from Pr. Marc Thiry (GIGA-Neurosciences, University of Liege, 
Belgium) and cultured at 37 °C in a humidified atmosphere and 5 % CO2 in DMEM (Dulbecco’s 
modified Eagle’s medium, Lonza, Verviers, Belgium) supplemented with 10 % (v/v) heat inactivated 
fetal bovine serum (FBS, Gibco, Life Technologies, Gent, Belgium). HCT116 cancer cells (human 
colorectal carcinoma cell line) were provided by Pr. Eric Verdin (Gladstone Institute, University of 
California, USA) and cultured in McCoy’s 5A (Lonza) supplemented with 10 % heat inactivated FBS. 
2.11. Cell viability (MTS) and cytotoxicity (LDH) assays 
HUVEC were seeded in a 96-well plate at a density of 8.104 cells/well and incubated for 48 hours. 
Polyplex nanoparticles, at a concentration of 100 nM GL3 siRNA (N/P 40), were added to the cells in 
100 µL of Opti-MEM® and incubated for 3 hours and then washed. Cell viability and cytotoxicity of 
polyplex nanoparticles were determined 24 hours later using MTS assay (CellTiter 96® AQueous One 
Solution Cell Proliferation Assay, Promega, WI, USA) or LDH assay (Cytotoxicity Detection KitPLUS, 
Roche, Basel, Switzerland), according to manufacturers’ instructions. 
2.12. Hemocompatibility assays 
Hemolysis, platelet aggregation and coagulation (calibrated thrombin generation test) were tested using 
protocols described previously 41 and using a final concentration of polyplex nanoparticles of 100 nM 
GL3 siRNA (N/P 40). For hemolysis assay, Triton X-100 (1 %) was used as technical positive control 
to fix the 100 % hemolysis value. 
2.13. In vivo biodistribution in mice 
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All procedures for xenograft tumor mouse model were approved by the Animal Welfare Committee of 
the University of Liege (approval #1748). 3x106 HeLa cells in 200 µL PBS were subcutaneously injected 
into the right flank of 8 weeks-old male NOD-SCID mice (Charles River, MA, USA). Four weeks after 
inoculation, when the tumor size reached ~500 mm3, a single dose of polyplexes containing 1 mg/kg 
Alexa Fluor® 660 HDAC5 siRNA at N/P 40 (100 µL) were injected into the tail vein. Four hours post-
injection, mice were anesthetized with isoflurane and images of the full animal fluorescence were 
recorded by Xenogen IVIS-200 System (PerkinElmer, MA, USA) using Cy5.5 filters. Mice were then 
sacrificed and fluorescence intensity of their organs was examined ex vivo. 
2.14. Cellular uptake 
Alexa Fluor® 546 labeled siRNA fluorescent polyplexes were formed at a concentration of 600 nM (N/P 
40) and then diluted to 100 nM in Opti-MEM® (Invitrogen, Gent, Belgium) and FBS to reach a final 
concentration of 0, 10, 30, or 50 % FBS (v/v). These samples were preincubated 1 hour at 37 °C and 
then added to HeLa cells for 3 hours. Cells were washed with PBS, trypsinized and collected into 
complete DMEM medium. Samples were centrifuged 4 minutes at 250 g at room temperature and 
suspended in 350 µL PBS. 104 cells were analyzed using a FACSCalibur flow cytometer (BD 
Biosciences, FACSCalibur, USA). Data were analyzed using CellQuest Pro software (BD Biosciences, 
USA).  
2.15. RT-qPCR 
mRNA expression was determined on HeLa cells 48 hours after transfection, using quantitative real-
time PCR. Protocol is detailed in our previous publication.25 In the case of a second treatment, 
transfection was repeated after 24 hours and cells were incubated for the remaining 24 hours. 
2.16. Proliferation assay and western blot 
4x104 transfected HCT116 cells were seeded in 24-well tissue culture plates in complete medium and 
were harvested at the indicated time-points. The cell numbers were indirectly determined using Hoechst 
incorporation (Bisbenzimide H33258, Calbiochem, Merck, Nottingham, UK), as previously described.49 
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Protein expression in these cells at different time points was determined by western blot using the 
protocol described in our previous work.25 
2.17. Statistical analysis 
Experiments were performed in triplicate (n=3), unless otherwise stated. Values are given as means ± 
standard deviation (SD). Statistical tests used are described in legends of related figures. * p<0.05, ** 
p<0.01 or *** p<0.001 were considered statistically significant.   
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3. Results 
3.1. Polyplexes characterization and siRNA complexation 
Formation of polyplexes is due to electrostatic interaction between cationic functional groups present 
on the polymer structure with anionic phosphate function of the siRNA. Size, zeta potential and 
complexation of siRNA are closely related to the N/P ratio. To select the optimal N/P ratio, particles 
were characterized in buffer from N/P 10 to N/P 60, at a fixed siRNA concentration of 100 nM (Fig. 
S1). Based on these results, an optimal N/P ratio of 40 was selected for next experiments. N/P 40 is the 
minimum ratio to achieve a maximal encapsulation of the siRNA (close to 100%) while attaining the 
surface size and charge equilibrium and avoiding an excess of polymer. 
Physicochemical characteristics at N/P 40 are detailed in Table 2. PEGylated and non-PEGylated 
polyplexes show similar siRNA complexation capacities, around 100 %. The hydrodynamic diameter 
was slightly higher for the non-PEGylated polymer (P-G-M). Polydispersity Index (PDI) was below 0.3 
for P-G-M and P-G-M-PEG750, indicating nearly monodisperse sample. P-G-M-PEG2000, with a PDI of 
0.34, presents a higher but moderate polydispersity.  
Table 2. Physicochemical characteristics of polyplex nanoparticles at N/P 40. Values represent mean ± SD (n=3). 
Polyplex 
nanoparticle Size (nm) PDI Zeta potential (mV) 
siRNA complexation 
(%) 
P-G-M 223 ± 18 0.24 ± 0.05 11.2 ± 0.9 100.4 ± 0.4 
P-G-M-PEG750 151 ± 20 0.22 ± 0.02 8.2 ± 1.1 97.8 ± 0.6 
P-G-M-PEG2000 150 ± 25 0.34 ± 0.08 5.0 ± 0.9 100.0 ± 0.1 
 
Morphology of these nanoparticles was determined by transmission electron microscopy (TEM). TEM 
images at different magnifications (Fig. 2) show the spherical morphology of polyplex nanoparticles. 
The three samples show a smaller size with TEM, around 100 nm, than values measured by DLS (Table 
2). This is due to the fact that DLS determines the hydrodynamic diameter of samples in the aqueous 
buffer, while TEM measure size of particles in the dry state. 
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Fig. 2. TEM images of P-G-M, P-G-M-PEG750 and P-G-M-PEG2000 polyplexes at different magnifications. 
3.2. Nuclease resistance 
To verify the ability of polymers to protect siRNA from nucleases, gel retardation assay was performed 
after incubation with RNase A for 1 hour, followed by its inhibition by RNase OUT, and the release of 
siRNA from polyplexes with heparin. Fig. 3 shows that the siRNA is protected when complexed in both 
PEGylated (Fig. 3B) and non-PEGylated (Fig. 3A) polyplex nanoparticles compared to naked control 
siRNA, which is immediately fully degraded. 
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Fig. 3. Nuclease resistance of siRNA complexed in polyplex nanoparticles. Gel retardation assay was performed after 
incubation in presence (+) or absence of (-) RNase A for 1 hour, followed by its inhibition by RNase OUT, and the release of 
siRNA with heparin. (A: P-G-M; B: P-G-M-PEG750 and P-G-M-PEG2000.)  
3.3. Polyplexes behavior in the presence of FBS 
Behavior of PEGylated and non-PEGylated nanoparticles in the presence of serum was evaluated using 
different techniques. First, interaction of polyplex nanoparticles with BSA was evaluated using ITC. Then, 
the effect of PEG750 and PEG2000 grafted polymers on behavior in the presence of FBS was evaluated in terms 
of siRNA release (FCS) and aggregation (fSPT), compared to non-PEGylated polyplexes.  
3.3.1. Interaction of polyplexes with BSA 
In order to study the interactions of the investigated nanoparticles with serum proteins, nanoparticles were 
titrated with BSA, a blood model protein, using ITC. This system records the heat generated by the 
association of the binder with its ligand and following progressive saturation, the binding enthalpy, the 
affinity constant and the stoichiometry are usually derived by fitting of a Wiseman plot (Fig. 4). Titration of 
the investigated nanoparticles with BSA showed a low affinity system, with dissociation constants in the mM 
range. For such low affinity systems, full saturation by the ligand cannot be reached even at the high 
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concentration of BSA used which is the maximal solubility limit in the titration syringe. Accordingly, only a 
partial binding isotherm is recorded (Fig. 4) and one of the fitted variables has to be kept constant.50 In 
previous studies, stoichiometry was the fixed variable as this parameter can be confidently obtained from 
known chemical or macromolecular structures. This is obviously not valid for nanoparticles that can bind an 
unknown number of protein molecules. However, the binding enthalpies are generally in the range of 5 
kcal/mol and this value was kept constant for a comparative analysis. Accordingly, the reported data should 
be regarded as apparent values. As indicated in Table 3, the BSA binding ability of the three types of 
nanoparticles does not differ significantly, although P-G-M-PEG2000 displays a slightly lower affinity 
constant Ka for the serum protein. All particles roughly bind a tenfold molar excess of BSA (n) with respect 
with polymer concentration. The enthalpic and entropic contributions to ΔG°b suggest that the association is 
enthalpy-driven (favorable interactions such as H-bonds or van de Waals contacts) whereas the weak and 
unfavorable entropy may reflect a reduction of the degree of freedom upon BSA binding. This weak and 
unfavorable entropic term also suggests that the hydrophobic effect is not significantly involved in BSA 
binding.51  
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Fig. 4. Isothermal titration calorimetry of BSA binding to polyplex nanoparticles P-G-M-PEG2000 at 25 °C. Upper panel: 
exothermic microcalorimetric traces of BSA (5 mM) injections into nanoparticle solution (11 µM). Lower panel: Wiseman plot 
of heat releases versus molar ratio of injectant/polymer in the cell. 
Table 3. Binding parameters of BSA association with nanoparticles at 25 °C 
Polyplex 
nanoparticle n 
Ka 
(103 M-1) 
ΔG°b 
(kcal mol-1) 
ΔH°b(a) 
(kcal mol-1) 
TΔS°b 
(kcal mol-1) 
P-G-M 9.7 ± 0.3 2.1 ± 0.1 -4.5 -5.0 -0.5 
P-G-M-PEG750 9.1 ± 0.2 2.3 ± 0.1 -4.6 -5.0 -0.4 
P-G-M-PEG2000 12.8 ± 0.2 1.7 ± 0.1 -4.4 -5.0 -0.6 
 (a) Fixed value for nonlinear fit of the binding isotherm for n equivalent binding sites 
3.3.2. siRNA release in the presence of FBS 
The possible destabilization of polyplexes by serum proteins and so, the siRNA release was determined 
using FCS before and after 1, 2, and 3 hours of incubation with 10 % or 50 % FBS (v/v). Fig. 5 shows 
the percentage of complexed siRNA over time, in 10 % (A) or 50 % FBS (B). In the presence of 10 % 
FBS, the release of siRNA is low, especially for non-PEGylated polyplexes (P-G-M). After 3 hours, 
13 %, 31 % and 35 % of siRNA are released from P-G-M, P-G-M-PEG750, and P-G-M-PEG2000, 
respectively. In the presence of 50 % FBS, around 50 % siRNA is released from both PEGylated and 
non-PEGylated formulations after 1 hour. However, this siRNA release remains constant up to 3 hours 
of incubation. 
3.3.3. Size distribution in the presence of FBS 
The size distribution and aggregation profile of the studied formulations was obtained by fSPT, a 
powerful technique to follow the size of fluorescent nanoparticles in a protein-rich medium, like FBS. 
The great advantage of this method compared to DLS is the possibility to detect only fluorescent 
nanoparticles, not taking into account all other components of biological fluids (e.g. proteins, enzymes, 
etc.), whereas DLS is best suited for aqueous solutions. Size distributions in TE buffer, and after 1 or 3 
hours incubation with 10% FBS were compared. In TE buffer, the average diameter of P-G-M 
polyplexes (Fig. 5C) was around 220 nm. One hour after FBS incubation, the size distribution became 
bimodal, with a peak around 111 nm and the second peak around 450 nm. After 3 hours, the intensity 
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of the 450 nm peak increased while the 111 nm peak decrease, showing an increase in size of the 
polyplexes over time. For P-G-M-PEG750 particles (Fig. 5D), the average size in buffer was 135 nm, 
increasing to 275 nm after 1 hour of incubation with FBS. Between 1 and 3 hours, the size remains 
constant, but with an initial increase of size in the presence of FBS. Finally, P-G-M-PEG2000 polyplexes 
(Fig. 5E) showed a size around 260 nm in buffer. However, the behavior in the presence of FBS is 
similar to P-G-M-PEG750 polyplexes, with an initial increase of the size becoming stable after 1 hour 
(around 510 nm). These size distributions were also evaluated by DLS (Fig. S3-S4). DLS results show 
that the size increase is greater for non-PEGylated compared to PEGylated polyplexes, with a diameter 
around 600-700 nm. The size of P-G-M-PEG750 and P-G-M-PEG2000 is around 300 nm directly after 
FBS addition, increasing slightly and stabilizing close to 400 nm, from 1 to 3 hours. Unfortunately, it 
was not possible to record size distribution in 50% FBS due to the 50% release of siRNA, making the 
dispersion medium too fluorescent to clearly distinguish diffusing nanoparticles. 
 
Fig. 5. siRNA complexation rate and size evolution in the presence of FBS. siRNA complexation rate of the three different 
polyplexes determined by FCS, in TE buffer (time = 0) and following 1 hour, 2 hours, and 3 hours incubation at 37 °C with 
10% (A) or 50% FBS (B). Size distributions determined by fSPT, in TE buffer and following 1 hour and 3 hours incubation in 
10% FBS at 37 °C, for P-G-M (C), P-G-M-PEG750 (D), and P-G-M-PEG2000 polyplexes (E). The Y-axis refers to the fraction 
(f) of polyplexes that appear with the corresponding size on the X-axis. 
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3.4. Toxicity on endothelial cells (HUVEC) 
In vivo, before to reach the cells, polyplex particles will be in contact with various elements dispersed 
in blood that can interact with the particles together with negatively charged blood vessel endothelium. 
Endothelial cells are one of the first elements that polyplex nanoparticles will encounter. In order to 
have an idea of the toxicity of polyplexes for blood vessel endothelium, the toxicity on primary human 
endothelial cells (HUVEC) was evaluated in vitro using MTS viability and LDH cytotoxicity assays. 
Cells were treated for 3 hours with 100 nM siRNA complexed with the three different polymers and 
cytotoxicity was measured 24 hours later. As shown in Fig. 6, both MTS and LDH assay demonstrate 
that the cytotoxicity of these polycarbonate polymers is low and non-significantly different from the 
negative control (PBS).  
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Fig. 6. Toxicity of polyplex nanoparticles on primary endothelial cells. (A) Cell viability (MTS assay) of HUVEC cells treated 
for 3 hours with different nanoparticles at a concentration of 100 nM in siRNA, washed and then cultured for additional 24 
hours. The percentage is related to non-treated cells (100%), and blank wells without cells (0%). (B) Cytotoxicity (LDH assay) 
of HUVEC cells treated for 3 hours with different nanoparticles at a concentration of 100 nM in siRNA, washed and then 
cultured for additional 24 hours. The percentage is related to positive control (Triton X-100 1%, cytotoxicity of 100%), and 
blank wells (without cells, cytotoxicity of 0%). Statistical comparison with negative control (PBS) was performed by using 
one-way ANOVA, followed by the Dunnett’s test (n=4). 
3.5. Hemocompatibility 
To evaluate the compatibility of polyplex nanoparticles formulation with an intravenous injection, 
hemocompatibility assays were performed. Results show that P-G-M, P-G-M-PEG750, and P-G-M-
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PEG2000 nanoparticles did not induce hemolysis in whole blood (Fig. 7A) and in washed RBC (Fig. 
S5A). Next, platelet aggregation was evaluated, after 1 hour incubation, in the presence of different 
polyplex nanoparticles and different inducers (Fig. 7B for collagen, Fig. S5B for ADP and S5C for 
arachidonic acid). At the investigated concentrations, P-G-M, P-G-M-PEG750, and P-G-M-PEG2000 did 
not significantly affect platelet aggregation, regardless the inducer used. Finally, in order to evaluate 
their potential interferences on coagulation process, nanoparticle formulations were tested with 
calibrated thrombin generation test. Fig. 7C shows representative thrombin activity profile induced by 
tissue factor in the presence of polyplex nanoparticles. From these profiles, control parameters (lag time 
(7D), peak (7E), and Endogenous Thrombin Potential (ETP) (7F)) were extracted, normalized and 
compared to negative control, PBS. No significant difference was observed, showing no pro- or 
anticoagulation activity.  
 
Fig. 7. Hemocompatibility assays of polyplex nanoparticles, performed at a final concentration of siRNA of 100 nM. (A) 
Human RBC lysis (% of hemolysis) in whole blood after 1.5 hour incubation. Triton X-100 1% and PBS were respectively 
used as positive and negative controls. (B) Platelet aggregation induced by collagen in the presence of the different 
formulations. PBS is used as negative control. Results are expressed as % of response, normalized with PBS. (C) 
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Representative thrombin activity profile induced by tissue factor in the presence of nanoparticles or PBS (negative control). 
Control parameters (lag time (D), peak (E), and ETP (F)) of these thrombin activity profiles were expressed as %, normalized 
with PBS values. Statistical comparisons with negative controls were performed by using one-way ANOVA, followed by the 
Dunnett’s test. 
3.6. In vivo biodistribution on mice 
The in vivo biodistribution of Alexa Fluor® 660 HDAC5 labeled siRNA delivered alone or complexed 
with P-G-M, P-G-M-PEG750, or P-G-M-PEG2000 polyplex nanoparticles was examined after intravenous 
(IV) administration. First, we followed the accumulation of polyplexes in living mice 4 hours and 24 
hours post injection of 1 mg/kg fluorescent siRNA in P-G-M-PEG750. Fig. 8A shows that the siRNA 
already accumulates at the tumor site 4 hours post IV injection. This fluorescence at the tumor site 
decreases but still remains after 24 hours. Experiments of ex vivo imaging on tumors and principal 
organs were therefore performed 4 hours post IV injection. Fig. 8B shows a tumor accumulation of 
Alexa Fluor® 660 siRNA only in mice treated with P-G-M, P-G-M-PEG750 and P-G-M-PEG2000 polyplex 
nanoparticles. No siRNA was detected in the tumors when mice were untreated or treated with free 
siRNA. Fluorescent siRNA was detected in the liver in all conditions except untreated mice, as well as 
in kidneys and the spleen, but in a lower level. P-G-M polyplexes show a high accumulation in lungs. 
To better distinguish the difference between tumors, fluorescence of the same tumors but with a different 
fluorescence scale is shown on Fig. 8C. Fluorescence seems to be slightly lower in tumors treated with 
P-G-M.  
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Fig. 8. In vivo biodistribution of Alexa Fluor® 660 labeled HDAC5 siRNA on mice. (A) Fluorescence intensity on living mice, 
4 hours and 24 hours post-IV injection of 1 mg/kg fluorescent siRNA in P-G-M-PEG750 nanoparticles. (B) Ex vivo imaging on 
tumors and principal organs performed 4 hours post-IV injection of 1 mg/kg of free siRNA, or complexed in P-G-M, P-G-M-
PEG750 or P-G-M-PEG2000 nanoparticles. (C) Ex vivo imaging on the same tumors but with a narrower fluorescence scale. 
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3.7. Cellular Uptake 
Cellular uptake was first determined is serum-free conditions (Opti-MEM®). To evaluate the effect of 
high amount of proteins in the medium on the cellular uptake, flow cytometry was performed after 
preincubation of polyplexes in medium supplemented with 10, 30, or 50% FBS. The Mean Fluorescent 
Intensity (MFI) of HeLa cells was evaluated 3 hours after transfection, indicating the mean amount of 
fluorescent siRNA uptaked by cells.  
In serum-free conditions, P-G-M and P-G-M-PEG750 nanoparticles present a significantly better uptake 
than P-G-M-PEG2000. After 1 hour of preincubation in 10 % FBS, the cellular uptake is significantly 
decreased, except for P-G-M-PEG2000. The cellular uptake of these nanoparticles is not significantly 
different from serum-free conditions, contrarily to P-G-M and P-G-M-PEG750. With 30 % and 50 % 
FBS, the decreased uptake is even more pronounced for the PEGylated nanoparticles, with a MFI close 
to 0 compared to non-PEGylated polyplexes.  
 
Fig. 9. Cellular uptake in serum-free medium and in the presence of different concentrations of FBS. Mean Fluorescence 
Intensity (MFI) of HeLa cells treated with polyplexes nanoparticles containing fluorescent siRNA, after 1 hour of incubation 
in Opti-MEM® containing 0, 10, 30 or 50 % FBS at 37 °C. MFI is normalized to untreated control cells. Statistical analysis 
was performed by using two-way ANOVA, followed by a Bonferroni’s test. 
3.8. In vitro efficiency: mRNA, protein silencing, and biological activity 
The ability of polyplexes to decrease the expression of HDAC5 mRNA was investigated by quantitative 
real-time RT-PCR, 48 hours after the treatment of HeLa cells in serum-free conditions. To exclude non-
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specific effects of polymers, the relative HDAC5 mRNA expression was normalized to cells treated 
with the same polyplexes but containing irrelevant GL3 siRNA. The mRNA shutdown was evaluated 
after 1 and 2 treatments with polyplexes. As shown in our previous publication, the P-G-M polyplexes 
were capable of decreasing the expression of HDAC5 (mRNA and protein) of about 50 % after one 
treatment 25. With a second dosing, efficiency was increased: the relative mRNA expression was reduced 
from 50 % to 20 % (Fig. 10A). To assess the biological relevance of HDAC5 depletion in cancer cells, 
a proliferation assay was performed on HCT116 human colorectal carcinoma cells. Cells were treated 
twice (Fig. 10C) with P-G-M containing HDAC5 or control GL3 siRNA, then reseeded at equal 
densities and harvested at the indicated time-points. As shown in Fig. 10C, the HDAC5 mRNA shut-
down leads to a significant decrease of cancer cells proliferation. To assess the relative HDAC protein 
expression at different time points of the proliferation curve, western blot was performed and showed a 
high decrease of HDAC expression. This protein shut down is the highest after 48 h and is correlated to 
mRNA expression values (Fig. 10E). 
Contrarily, one treatment with PEGylated polymers is not enough to significantly reduce the expression 
of HDAC5 mRNA. A second treatment increased this efficiency, especially for P-G-M-PEG2000 
polyplexes, with a relative expression of HDAC5 mRNA decreasing to 52 % (Fig. 10B). However, this 
decrease of HDAC5 mRNA expression of around 50 % for two treatments of P-G-M-PEG2000 
polyplexes, related to the HDAC protein expression decrease observed by western blot (Fig. 10F), is 
not sufficient enough to observe a significant decrease of cell proliferation (Fig. 10D). 
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Fig. 10. In vitro efficiency of polyplex nanoparticles. Relative HDAC5 mRNA expression in HeLa cells determined by RT-
qPCR 48 h after the first transfection with P-G-M (A), or P-G-M-PEG750 and P-G-M-PEG2000 (B) polyplexes, treated 1 or 2 
times. Values were normalized to β-actin, and expressed relative to the value of irrelevant siRNA-transfected. Statistical 
analysis was performed by using one-way ANOVA, followed by a Dunnet’s test compared to control value of 100 %. 
Proliferation assay on HCT116 cells after two treatments with P-G-M (C) or P-G-M-PEG2000 polyplexes (D). Statistical 
analysis was performed by using one-way ANOVA, followed by a Bonferroni’s test compared to the related GL3 control 
condition. Only cells treated with P-G-M polyplexes showed a significant decrease in proliferation. Silencing of HDAC5 
protein in HCT116 cells treated with P-G-M (E) and P-G-M-PEG2000 (F) polyplexes, at different time points of the proliferation 
curves.  
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4. Discussion and conclusions 
The objective of this work was to evaluate PEGylated and functionalized aliphatic polycarbonate 
polyplex nanoparticles to administer intravenously HDAC5 siRNA to tumor cells, in order to decrease 
their proliferation. We compared newly synthesized P-G-M-PEG750 and P-G-M-PEG2000 polymers to 
non-PEGylated P-G-M polymer, for which in vitro efficiency has been shown previously 25. 2000 Da 
PEG chain is described in the literature as sufficient to provide stealth properties to nanoparticles 43. 
However, PEG is also known to limit interactions with cellular membranes and thus efficiency of 
polyplexes. For this reason, a shorter PEG chain of 750 Da was also used to limit this possible decrease 
in efficiency along with keeping sufficient stealth properties. 
First, physicochemical characteristics of polyplexes were determined in order to evaluate the influence 
of covalently linked PEG chain to P-G-M polymer on polyplexes formation. The effect of different N/P 
ratios (between 10 and 60) on siRNA encapsulation rates, polyplex size and surface charge was tested. 
In order to be under suitable conditions for a future IV administration of the polyplexes, these effects 
were measured in a buffer (pH 7.4), isotonized with mannitol. Indeed, as shown by Machinskaya et al.52 
the physiological ionic strength may play important roles in the case of polyplexes used in gene 
transfection in terms of stability and destabilization of the polynucleotide component. As expected, we 
observed an increase in the encapsulation with the increase of the N/P ratio, that the sizes of the 
polyplexes stabilize from a certain N/P and that the surface charge gradually increases to reach a plateau 
also from a certain N/P. The N/P 40 selected corresponds, for the three tested polymers, to the N/P which 
allows the encapsulation of almost 100% of the siRNA, to form polyplexes with a stable size compatible 
with IV administration and to reach the surface charge plateau. N/P 40 is the minimum ratio allowing 
to combine these optimal characteristics for IV administration while avoiding an excess of cationic 
polymer and therefore of positive charges. 
PEGylated and non-PEGylated polycarbonate polymers are able to form polyplex nanoparticles 
possessing physico-chemical characteristics required for IV administration (Table 2).53 In terms of size, 
diameter is slightly lower for PEGylated nanoparticles, around 150 nm, compatible with passive 
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targeting through the “EPR effect.”18 As expected, zeta potential decreases with the presence of PEG, 
according to chain length, from +11.2 mV for P-G-M nanoparticles to +5 mV for P-G-M-PEG2000 
polyplexes. This positive charge is helpful to interact with plasma membrane.54 Unlike the PEGylated 
particles, P-G-M polyplexes have a tendency to form aggregates, as shown by TEM (Fig. 2), because 
of too low electrostatic and steric repulsion between these nanoparticles. In terms of electrostatic 
repulsion, a colloidal suspension in considered unstable if the zeta potential value is between -30 and 
+30 mV.55 This lower stability has been confirmed by DLS, showing a size increase over time, especially 
for non-PEGylated polyplexes (Fig. S2). Nuclease resistance assay shows a protection of the siRNA in 
the three polyplexes formulations. PEGylated and non-PEGylated polycarbonate polymers form 
nanoparticles with good physicochemical characteristics but the presence of PEG seems to increase 
colloidal stability proportionally to chain length, thanks to steric hindrance.56 
As PEG was added on the P-G-M polymer structure in order to decrease interactions with blood 
constituents, different techniques were used to evaluate interactions between polyplexes nanoparticles 
and plasma proteins. 
First, ITC study has been used to evaluate interaction of polyplex nanoparticles with BSA, used as blood 
reference protein. According to the results (Fig. 4), we can conclude that the three polyplex formulations 
cannot be clearly distinguished regarding their binding properties with BSA. Only PEG2000 statistically 
reduces the affinity between particles and BSA compared to non-PEGylated particles. However, all the 
values are low and the observed difference should not be significant in vivo. As shown by Leclercq et 
al.42, even if albumin adsorption is minimized by the presence of PEG, albumin layers are present on 
both pegylated and non-pegylated surfaces, even if it is in different amounts. The repulsive effect 
assigned to pegylated surfaces in contact with blood is probably due to the presence of adsorbed albumin 
even if the deposition of this protein from blood is likely to be not as specific as when the albumin is 
alone in solution according to data collected for mixtures of proteins.  
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As explained in the introduction, the negatively charged proteins present in the FBS can compete with 
the siRNA complexation.37 At a concentration of 10 % FBS, the competition highlights the difference 
of affinity between polymers and siRNA (Fig. 5A). The lower release of siRNA from P-G-M polyplex 
nanoparticles compared to PEGylated ones can be explained by a stronger electrostatic interaction 
between the positively charged polymer and negatively charged siRNA. Indeed, the presence of PEG 
groups grafted on the polymer may hamper the formation of electrostatic interactions with the siRNA. 
In the presence of 50 % FBS, around 50 % of siRNA is released from polyplexes nanoparticles already 
after 1 hour (Fig. 5B). Similar values were observed for all polyplex nanoparticles, PEGylated or not, 
due to the presence of a high amount of negatively charged proteins, which strongly compete with 
siRNA on the binding to the polymer.37 At high FBS concentration, the competition is saturated and no 
difference can be seen between formulations. As the competition phenomenon is saturated, the 
complexation rate remains constant up to 3 hours. The fact that 50 % of the siRNA remains associated 
with the polymer after 3 hours of incubation in a protein-rich environment indicates relatively stable 
nanovectors in terms of cargo release.37, 57-58 However, in vitro the concentration of interacting proteins 
is fixed. In blood, releasing proteins will be renewed and thus all the siRNA should be released. 
Moreover, in vivo, a Vroman effect may be feared meaning that some proteins with higher affinity will 
lead to stable combinations which will result in the release of the siRNA. 
According to fSPT results (Fig. 5C-E), a size increase is observed over time for the non-PEGylated 
nanoparticles in the presence of 10 % serum, probably because of the formation of aggregates. If a major 
population of polyplexes remains in a size range compatible with intravenous administration (< 300 
nm), particles with 1µm are also present at 3h.53 P-G-M-PEG750 and P-G-M-PEG2000 nanoparticles also 
exhibit an initial growth due to the presence of 10 % serum, higher for P-G-M-PEG2000 than for P-G-M-
PEG750. However, their size is stable over time and does not increase anymore after 1 hour of contact 
with the serum components. PEG does not appear to completely prevent the formation of the protein 
corona around polyplexes but appears to have a role in the stability of the particle size over time. 
Overall, differences in the behavior of the PEGylated of non-PEGylated formulations in the presence of 
serum are negligible. P-G-M polyplexes show, surprisingly, moderate interactions with plasma proteins. 
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One possible explanation is that the morpholine block of the polycarbonate polymer is disposed on the 
surface of P-G-M polyplexes. This block is hydrophilic but not charged at a neutral pH, and thus can 
play a role similar to PEGylation. Forming a hydrated corona around the nanoparticle, neutral 
morpholine block could reduce interactions between the anionic proteins and cationic guanidine 
functions.44 
To validate the in vitro assays showing negligible differences between the three formulations, 
biodistribution study on mice after IV injection was performed to highlight in vivo differences between 
PEGylated and non-PEGylated nanoparticles. Considering that these polyplex nanoparticles cause no 
cytotoxicity endothelial cells (Fig. 6) and have no effect on both hemolysis and coagulation (Fig. 7), 
their intravenous injection can be considered without alterations of normal blood function. These results 
have a high importance, since a release of hemoglobin can lead to adverse effects, like renal toxicity, 
anemia, and pulmonary hypertension.59 The in vivo study showed an accumulation of polyplex 
nanoparticles at the tumor site thanks to the EPR effect, compared to naked siRNA, despite accumulation 
in certain organs such as the liver and spleen (Fig. 8). These organs possess a fenestrated vasculature 
and are able to capture a certain proportion of the nanoparticles with a diameter higher than 200 nm.53 
As observed previously by others40, P-G-M polyplexes exhibit pulmonary accumulation due to the 
retention of aggregates in the small capillaries of the lungs. Indeed, it is often described that particles in 
the micrometer range exhibit rapid accumulation in these capillaries.53 It would therefore appear that in 
the presence of blood, P-G-M polyplexes may form larger aggregates than those observed in the 
presence of 10 % serum. Addition of PEG seems here to promote the passive tumor targeting and 
decrease lung accumulation, probably because of higher blood stability of PEGylated polyplexes. But 
these results show no difference between the PEG750 and PEG2000. Addition of PEG is necessary in order 
to avoid occlusion of pulmonary capillaries and lethal toxicity40. However, these results should be 
interpreted with caution because of the small number of mice tested. 
It is known that PEGylation can partially mask the positive surface charge of polyplexes, with a 
consequent reduction of the interaction of nanoparticles with the plasma proteins, but also with the 
cellular membranes.60-61 This dilemma can result in a decrease of the efficiency by decreasing cellular 
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uptake and endosomal escape, in proportion to the chain length and density.62 The possible decrease in 
cellular uptake and mRNA degradation has been therefore tested in vitro. 
Cellular uptake in serum-free conditions (Opti-MEM®Error! Reference source not found.) is 
decreased for P-G-M-PEG2000 compared to P-G-M and P-G-M-PEG750 polyplexes. This decrease is 
probably due to weaker interactions with cells because of large PEG chain, masking the surface of 
polyplex nanoparticles.61 However, PEG750 does not seem to reduce interaction between polyplexes and 
cell membrane, probably due to the shorter chain length.43 
To be closer to physiological conditions, cellular uptake has been performed in presence of serum. 
Indeed, the presence of a protein-rich environment can cause a loss of activity in vitro, compared to 
serum-free conditions.63 In the presence of serum, cellular uptake of the three formulations is greatly 
reduced, compromising the efficiency of these polyplexes in biological conditions. Clearly, P-G-M 
polyplexes cellular uptake is less influenced by the presence of high amounts of FBS. The decrease in 
cellular uptake can generally be explained by (i) a premature release of siRNA from nanoparticles in the 
presence of FBS, (ii) an increase of the size that can interfere with endocytosis mechanisms and/or (iii) 
the formation of a protein corona on the surface of polyplexes that can modify the surface properties of 
nanoparticles and their ability to interact with plasma membranes.63-65 In the case of PEGylated and non-
PEGylated P-G-M nanoparticles, the uptake differences cannot be explained by a different release of 
siRNA or increase of polyplex size, according to Fig. 5. Differences in the protein-corona composition 
could explain differences in uptake of PEGylated and non-PEGylated nanoparticles in concentrated FBS 
medium.64 Anyhow, these data suggest that such a reduction in cellular entry might be associated with 
a loss of efficiency compared to serum-free in vitro conditions. 
In vitro, P-G-M polyplex nanoparticles are able to deliver siRNA into the cytoplasm to degrade HDAC5 
mRNA in serum-free conditions, leading to a protein shutdown and a decrease in proliferation of cancer 
cells (Fig. 10A, C, E). However, PEGylated polyplex nanoparticles have a lower in vitro efficiency in 
terms of decrease of HDAC5 mRNA and protein expression, compared to non-PEGylated nanoparticles. 
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This decrease of mRNA shutdown efficiency leads to the loss of the antiproliferative effect on cancer 
cells obtained for P-G-M nanoparticles (Fig. 10B, D, F).  
In this study, the efficiency of P-G-M-PEG2000 is higher than P-G-M-PEG750, despite the lower cellular 
uptake. A possible explanation to this observation is the difference of the morpholine/guanidine ratio 
between these two polymers. For P-G-M-PEG2000 polymer, the ratio is 1.5, compared to 1.2 for P-G-M-
PEG750 (Table 1). Previously, we showed that the buffer capacity of the polymer is directly related to 
this ratio,25 resulting in a possible higher endosomal escape for P-G-M-PEG2000 than P-G-M-PEG750, 
counterbalancing the lowest cellular uptake. However, P-G-M and P-G-M-PEG750 nanoparticles show 
similar cellular uptake in serum-free conditions and similar buffer capacity (Table 1). Differences of 
efficiency between these two polyplex nanoparticles are probably due to more complex intracellular 
mechanisms influenced by PEGylation that will require further investigations.62 
According to in vitro efficiency and cellular uptake in the presence of FBS, in vivo efficacy of PEGylated 
polyplexes seems compromised. Contrariwise, non-PEGylated polyplex nanoparticles seem to keep a 
part of their capacity to enter into cells in serum rich conditions and have good in vitro efficacy. In view 
of these results, non-PEGylated polyplex seems therefore more promising than PEGylated polyplex for 
in vivo efficacy. However, as shown by the in vivo study, these polymers appear to have a lesser 
accumulation in the tumor and a large unexplained accumulation in the lungs. Before considering in 
vivo efficacy using this polymer, it will be necessary to understand the reasons and the risks linked to 
this unexplained pulmonary accumulation.  
Although PEGylation is used in the clinic to increase the biological half-life and tumor passive targeting 
of clinically used liposomes-based nanoparticles, like Caelyx®, Doxil® and LipoDox® 66, this strategy 
seems to be not suitable for siRNA delivery. This paper raises the question of the relevance of this 
commonly described PEGylation strategy for siRNA delivery. Indeed, compared to small molecules like 
doxorubicin that are able to diffuse through cellular membranes after its release from the nanoparticle 
at the tumor site, siRNA needs to be complexed with its vector to cross cellular membranes, escape from 
the endosome and reach the cytoplasm.67 Unfortunately, PEGylation seems to interfere with these 
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crucial steps for effective siRNA delivery.60, 62 Moreover, our work highlights the necessity of carrying 
out in vitro tests in conditions closer to the physiological conditions than those conventionally used. 
This will allow to understand the in vivo studies and the numerous disappointments that result from 
them. The physicochemistry plays an important role in these phenomena and the literature is 
questionable when it forgets to take into account the interactions with blood and endothelial elements 
to consider in vitro investigations only.  
Because of this “PEG dilemma,” other strategies than classical PEGylation should perhaps also be 
considered in order to form nanoparticles with stealth properties and low protein interaction combined 
with high cellular uptake and biological efficiency in the presence of biological fluids, in order to 
combine tumor targeting and biological efficacy. One strategy could be the use of a labile bond between 
the PEG chain and the copolymer. This labile bond should be preferentially broken once the particle 
reaches the tumor site, exploiting tumor microenvironment, such as the decrease of the pH,68 or the 
overexpression of an enzyme, like the metalloproteinase.69 Another strategy could be the use of 
alternative polymers, non-covalently linked to the surface polyplexes, like hyaluronic acid, a 
biocompatible and non-immunogenic natural polymer. In addition to conferring steric hindrance and a 
negative charge to the surface of polyplexes, causing repulsion with plasma proteins, hyaluronic acid 
has a role of targeting ligand through the overexpression of CD44 receptor on the surface of many cancer 
cells.70 We are currently investigating this alternative strategy.  
In the field of HDAC and cancer therapy, researchers and clinicians do believe that isotype-specific 
HDAC inhibitors will result in more effective drugs, leading to development of plenty new specific and 
selective pharmacological molecules by pharmaceutical company. HDAC5 is emerging as a strong 
candidate for selective pharmacologic target inhibition in the oncology setting but some concerns exist 
about the ultimate goal of designing a pharmacological compound that selectively target this HDAC. 
Although a lot of work remains to be done to further improve the efficacy of these nanoparticles, HDAC 
inhibition-based cancer therapy might benefit from such delivery system to specifically target HDAC 
members soon.  
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